Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Bavarian Nordic options Prostvac to BMS; option exercise unlikely

Executive Summary

Bristol-Myers Squibb Co. received an option to exclusively license Bavarian Nordic AS's Phase III Prostvac (rilimogene galvacirepvec), a vaccine for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register